MAPK3 and idiopathic pulmonary fibrosis: While we are limited by the lung tissue samples of IPF patients to temporally analyze the changes of ERK1/2 activation, results from a previous study indeed suggest that ERK1/2 activation in epithelial and endothelial cells subsides accompanying the progression of fibrosis in IPF lungs [46].